SCHEMBL6857048

SCHEMBL6857048

CC(=O)C(=O)CC(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 1/20 0.38
CA4 P22748 2/20 0.37
TSHR P16473 2/20 0.35
THPO P40225 1/20 0.35
HMGCR P04035 1/20 0.35
CHRM1 P11229 1/20 0.35
TBXA2R P21731 1/20 0.35
ADRA1A P35348 1/20 0.35
CA1 P00915 3/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
HIF1A Q16665 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CA2 P00918 2/20 0.31
CA7 P43166 1/20 0.31
CA14 Q9ULX7 1/20 0.31
ALDH1A1 P00352 2/20 0.30
TDP1 Q9NUW8 1/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14914212 0.83 HMGCR (0.40) CES1TSHRHMGCRCHRM1TBXA2R
SCHEMBL13433276 0.77 TDP1 (0.36) TSHRHMGCRCHRM1TBXA2RADRA1A
SCHEMBL3697055 0.75 HMGCR (0.41) TSHRHMGCRCHRM1TBXA2RADRA1A
SCHEMBL13433277 0.75 MAPT (0.35) HMGCRCHRM1TBXA2RADRA1AHTT
SCHEMBL104505 0.73
SCHEMBL8874268 0.73 CA4 (0.40) CA4TSHRHMGCRCHRM1TBXA2R
SCHEMBL4444683 0.73 CES1 (0.36) CES1CA4TSHRTHPOCA1
SCHEMBL17664603 0.73 BLM (0.33) TSHRHMGCRCHRM1TBXA2RADRA1A
SCHEMBL1284011 0.73 HMGCR (0.33) TSHRHMGCRCHRM1TBXA2RADRA1A
SCHEMBL4647346 0.73 OR51E2 (0.38) TSHRHMGCRCHRM1TBXA2RADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9856279-B2 Therapeutically active compositions and their methods of use AGIOS PHARMACEUTICALS, INC. (US) 2018-01-02 US disclosed
US-20160229876-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE SERVIER PHARMACEUTICALS LLC 2016-08-11 US disclosed
US-20140256767-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS THE BROAD INSTITUTE, INC. (US) 2014-09-11 US disclosed
US-20140213580-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE AGIOS PHARMACEUTICALS, INC (US) 2014-07-31 US disclosed
US-20110130406-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-06-02 US disclosed
US-6790644-B2 ISOLATED FROM ACINETOBACTER JOHNSONII, WHICH DECONTAMINATES/ METABOLIZES ACETYLACETONE BIOCATALYTICS, INC. 2004-09-14 US disclosed
US-20030148487-A1 1,3-dicarbonyl-dioxygenase - a new c-c-bond cleaving enzyme CODEXIS, INC. 2003-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110130406-A1 PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS TYRO3, LCK, LTK CES1 2602/4885CA4 3402/4885TSHR 637/4885
US-20140213580-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE RNASE1, TP53, MCL1 CES1 1316/4885CA4 981/4885TSHR 4420/4885
US-20140256767-A1 DIRECT INHIBITORS OF KEAP1-NRF2 INTERACTION AS ANTIOXIDANT INFLAMMATION MODULATORS KEAP1, NFE2L2, HMOX1 CES1 1208/4885CA4 4445/4885TSHR 4696/4885
US-20160229876-A1 THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE MCL1, TP53, MMP8 CES1 1769/4885CA4 1489/4885TSHR 4636/4885
US-20030148487-A1 1,3-dicarbonyl-dioxygenase - a new c-c-bond cleaving enzyme ALDH7A1, CMBL, DDO CES1 139/4885CA4 635/4885TSHR 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.